Saruparib
1 clinical trial
2 abstracts
7 indications
Indication
Endometrial CancerIndication
Stomach CancerIndication
Ovarian CancerIndication
Colorectal CancerIndication
Bladder CancerIndication
Bile Duct CancerAbstract
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).Org: British Columbia Cancer Agency (BCCA), Vancouver Cancer Centre, Vancouver, BC, Canada, Huntsman Cancer Institute, Salt Lake City, UT, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, Urologicum Duisburg, Duisburg, Germany, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Brest, France, Kagawa University, Kagawa, Japan, Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom, Peter MacCallum Cancer Centre, Melbourne, Australia,
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2026-08-19